Pacira BioSciences (PCRX) EBIAT: 2010-2025
Historic EBIAT for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $5.4 million.
- Pacira BioSciences' EBIAT rose 103.79% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 123.63%. This contributed to the annual value of -$99.6 million for FY2024, which is 337.30% down from last year.
- As of Q3 2025, Pacira BioSciences' EBIAT stood at $5.4 million, which was up 212.07% from -$4.8 million recorded in Q2 2025.
- Pacira BioSciences' EBIAT's 5-year high stood at $25.8 million during Q2 2023, with a 5-year trough of -$143.5 million in Q3 2024.
- In the last 3 years, Pacira BioSciences' EBIAT had a median value of $9.0 million in 2024 and averaged -$4.7 million.
- As far as peak fluctuations go, Pacira BioSciences' EBIAT soared by 1,666.81% in 2023, and later plummeted by 1,421.29% in 2024.
- Over the past 5 years, Pacira BioSciences' EBIAT (Quarterly) stood at -$5.1 million in 2021, then crashed by 96.92% to -$10.1 million in 2022, then surged by 346.19% to $24.9 million in 2023, then slumped by 35.50% to $16.0 million in 2024, then skyrocketed by 103.79% to $5.4 million in 2025.
- Its EBIAT stands at $5.4 million for Q3 2025, versus -$4.8 million for Q2 2025 and $4.8 million for Q1 2025.